Completed PHASE4 INTERVENTIONAL 2-arm NCT00223964

Study of the Efficacy of Two Doses of Ferrlecit in the Treatment of Iron Deficiency in Pediatric Hemodialysis Patients

Randomized Double-Blind Parallel Group MultiCenter Study of the Efficacy of Two Doses of Ferrlecit® in Treatment of Iron Deficiency in Pediatric Hemodialysis Patients Receiving Epoetin.

Sponsor: Watson Pharmaceuticals

Conditions Anemia

Interventions Ferrlecit (sodium ferric gluconate complex in sucrose injection)

Updated 7 times since 2017 Last updated: Aug 10, 2012 Started: Jun 30, 2003 Primary completion: Oct 31, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00223964, this PHASE4 trial focuses on Anemia and remains completed. Sponsored by Watson Pharmaceuticals, it has been updated 7 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Jun 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Watson Pharmaceuticals

Data source: Watson Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aruascalientes, Mexico , Bashkortostan, Russia , Belgrade, Serbia , Bialystok, Poland , Birmingham, United States , Boston, United States , Gdansk, Poland , Kansas City, United States , Krakow, Poland , Lodz, Poland and 14 more locations